Treatment Optimisation Community Meeting
Date: 15 May 2017
Venue: Golden Peacock Hotel, Plot No 13/97, Area 13, Lilongwe, Malawi
1 day training, advocacy and strategy meeting before 11th INTEREST Workshop
Facilitators: Polly Clayden and Kenly Sikwese
Agenda
|
8.00 – 8.30 |
Arrival and coffee
Aims of the day and introductions – Kenly/Polly |
| 8.30 – 10.30 | Country feedback – TO initiatives since Yaoundé meeting |
| 10.30 – 11.00 | BREAK |
| 11.00- 12.00 | Update on the ADVANCE trial – Francois Venter, Wits RHI |
| 12.00 – 12.30 | Community mobilisation on the ADVANCE trial by TAC – Luckyboy Mkhondwane |
| 12.30 – 13.00 | CHAI CAB update – Kenly |
| 13.00 – 14.00 | LUNCH |
| 14.00 – 15.00 | CHAI in-country update |
| 15.00 – 15.30 | ART optimisation for Children |
| 15.30 – 15.45 | BREAK |
| 15.45 – 16.15 | Pipeline drugs – Francois Venter, Wits RHI |
| 16.15 – 17.15 | Andrew Hill presentations: 1. Universal access- HIV and beyond 2. Safety of new antiretrovirals |
| 17.15 – 17.30 | Next steps |
| 18.00 | Community dinner/reception |
Background reading for TO meeting:
- When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank
This is a review to discuss barriers and opportunities for the introduction of new antiretrovirals into national treatment programmes in low-income and middle-income countries to support further treatment scale-up. Invitees to a WHO Think Tank in February 2017 evaluated recently published results.
Andrew Hill’s presentation at the BHIVA Spring conference 2017. He discusses the new era of generic HIV drugs that are WHO approved, bioequivalent at low cost. Shouldn’t the NHS consider buying these?
The slides are here: The podcast is here:
- Fit for Purpose (July 2017)
The online version of FfP is here
Read full INTEREST meeting report here.